Pharmaceutical

Gilead Sciences Publishes 2023 ESG Impact Report

NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact…

2 months ago

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging

Integrated artificial intelligence (AI) and advanced tools improve image quality and exam speed to help providers make accurate diagnoses and…

2 months ago

Pro-ficiency Appoints Markus Saba, Pharmaceutical Industry Veteran, to Board of Directors

DURHAM, NC / ACCESSWIRE / April 18, 2024 / Pro-ficiency, a leading provider of simulation-based training and compliance solutions for…

2 months ago

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases

Advancing a broad portfolio designed to accelerate innovation and shape the future of treatment for weight loss, obesity-related conditions and…

2 months ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company’s In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management…

2 months ago

Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS…

2 months ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

2 months ago

Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will…

2 months ago

NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates

Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal…

2 months ago

PharmaCord Announces Leadership Expansion, Appointing Rob Brown to Chief Growth Officer

JEFFERSONVILLE, IN / ACCESSWIRE / April 17, 2024 / PharmaCord LLC, a leading provider of patient support services for the…

2 months ago